Newsletter sign up


Knowledge Center Our services

ADC Review
is made possible by:



Copyright 2014
Terms & Conditions


Profile Photo

About ADC Review

Articles by ADC

Duocarmycin Analogues

31 October

Duocarmycins are members of a small group of natural products that are notable for their extreme cytotoxicity and thus represent a class of exceptionally potent antitumour antibiotics.

Maytansine

31 October

[caption id="attachment_1196" align="alignleft" width="234"] Maytansine[/caption] Chemical Name: L-alanine, N-acetyl-N-methyl-, 11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dio...


Monomethyl Auristatin E (MMAE)

Published on 31st October

Monomethyl auristatin E (MMAE)
Monomethyl auristatin E (MMAE)

Chemical Name: (S)-N-((3R,4S,5S)-1-((S)-2-((1R,2R)-3-(((1S,2R)-1-hydroxy-1-phenylpropan-2-yl)amino)-1-methoxy-2-methyl-3-oxopropyl)pyrrolidin-1-yl)-3-methoxy-5-methyl-1-oxoheptan-4-yl)-N,3-dimethyl-2-((S)-3-methyl-2-(methylamino)butanamido)butanamide

Molecular Weight: 717.98
Formula: C39H67N5O7
CAS#: 474645-27-7
Solubility: DMSO up to 20 mM

Biological Activity
Monomethyl Auristatin E (MMAE, vedotin) is a very potent antimitotic agent that inhibits cell division by blocking the polymerisation of tubulin. [1,2,3] MMAE is 100-1000 times more potent than doxorubicin (Adriamycin/Rubex) and cannot be used as a drug itself.

However, as part of an antibody-drug conjugate or ADC, MMAE is linked to a monoclonal antibody (mAb) that recognizes a specific marker expression in cancer cells and directs MMAE to a specific, targeted cancer cell. The linker linking MMAE to the monoclonal antibody is stable in extracellular fluid, but is cleaved by cathepsin once the antibody-drug-conjugate has bound to the targeted cancer cell antigen and entered the cancer cell, after which the ADC releases the toxic MMAE and activates the potent anti-mitotic mechanism. Antibody-drug conjugates enhance the antitumor effects of antibodies and reduce adverse systemic effects of highly potent cytotoxic agents.[2,3,4,5]

Leave a Reply